Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
DBV Technologies S.A. (DBVT) Discusses Regulatory Update and FDA Interactions for Viaskin Peanut Patch in Young Children Transcript
DBV Technologies Provides BLA Submission Update for the VIASKIN® Peanut Patch in Children Aged 4 through 7 Years; Working Collaboratively with FDA to Optimize Review Process in Preparation for Filing
DBV Technologies Announces Inclusion in the Euronext Tech Leaders Index
DBV Technologies (DBVT) Soars 5.3%: Is Further Upside Left in the Stock?
DBV Technologies Revises Participation in the Goldman Sachs 47th Annual Global Healthcare Conference
DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026
DBV Technologies to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
DBV Technologies Announces the Results of its 2026 Combined General Meeting
DBV Technologies Announces First Participant Screened in THRIVE Phase 2 Study of the VIASKIN® Peanut Patch in Infants ages 6 through 12 Months with Peanut Allergy
Combined General Meeting of June 3, 2026
DBV Technologies to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq
DBV Technologies Reports First Quarter 2026 Financial Results
Is COMPASS Pathways (CMPS) Outperforming Other Medical Stocks This Year?
DBV Technologies: A Cohort-Driven Model That Could Support Blockbuster VIASKIN Revenue
DBV Technologies (DBVT) Upgraded to Buy: What Does It Mean for the Stock?
Wall Street Analysts Predict a 79.04% Upside in DBV Technologies (DBVT): Here's What You Should Know
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of March 31, 2026
DBV Technologies S.A. (NASDAQ:DBVT) Given Average Recommendation of “Moderate Buy” by Brokerages
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
DBV Technologies Reports Full Year 2025 Financial Results and Business Update
DBV Technologies to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review
DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Here’s What Happened
DBV Technologies to Participate in Upcoming March Investor Conferences
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting
DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of “Moderate Buy” from Brokerages
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
DBV Technologies (NASDAQ:DBVT) Shares Gap Down on Insider Selling
Bpifrance Epic Sells 1,292,103 Shares of DBV Technologies (NASDAQ:DBVT) Stock
Bpifrance Epic Sells 2,076,990 Shares of DBV Technologies (NASDAQ:DBVT) Stock
Peanut Allergy Patch For Kids? DBV Technologies Advances Toward FDA Filing
DBV Technologies S.A. (DBVT) Discusses Positive Phase III VITESSE Trial Results for Peanut Allergy Patch in Young Children Transcript
Here Are Monday’s Top Wall Street Analyst Research Calls: Bristol-Myers Squibb, GE Vernova, KLA Corp., Klaviyo, Las Vegas Sands, ServiceNow, and More
Here Are Wednesday’s Top Wall Street Analyst Upgrades and Downgrades: American Eagle Outfitters, Equinix, Garmin, Honeywell, Uber, Wendy’s and More
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
DBV Technologies (DBVT) Expected to Announce Quarterly Earnings on Wednesday
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
Strength Seen in DBV Technologies (DBVT): Can Its 6.8% Jump Turn into More Strength?
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
Peanut Allergy Clinical Trial Pipeline: Insights into a Growing Landscape with 12+ Companies Advancing Novel Treatments| DelveInsight
New Strong Sell Stocks for September 23rd